These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 9561340)

  • 1. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.
    Opal SM; Yu RL
    Drugs; 1998 Apr; 55(4):497-508. PubMed ID: 9561340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiendotoxin therapies for septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):44-52. PubMed ID: 8162353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endotoxin as a drug target.
    Opal SM; Glück T
    Crit Care Med; 2003 Jan; 31(1 Suppl):S57-64. PubMed ID: 12544978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies for sepsis: antiendotoxin therapies.
    Manocha S; Feinstein D; Kumar A; Kumar A
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1795-812. PubMed ID: 12457439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock.
    Pollack M; Ohl CA
    Curr Top Microbiol Immunol; 1996; 216():275-97. PubMed ID: 8791745
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-endotoxin therapeutic options for the treatment of sepsis.
    Lynn WA
    J Antimicrob Chemother; 1998 Jan; 41 Suppl A():71-80. PubMed ID: 9511089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic effects of endotoxin.
    Zivot JB; Hoffman WD
    New Horiz; 1995 May; 3(2):267-75. PubMed ID: 7583168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the lipopolysaccharides: still a matter of debate?
    Nahra R; Dellinger RP
    Curr Opin Anaesthesiol; 2008 Apr; 21(2):98-104. PubMed ID: 18443474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Endotoxin 9-Meric Peptide with Therapeutic Potential for the Treatment of Endotoxemia.
    Krishnan M; Choi J; Choi S; Kim Y
    J Microbiol Biotechnol; 2021 Jan; 31(1):25-32. PubMed ID: 33263333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins.
    Chen X; Dings RP; Nesmelova I; Debbert S; Haseman JR; Maxwell J; Hoye TR; Mayo KH
    J Med Chem; 2006 Dec; 49(26):7754-65. PubMed ID: 17181157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock.
    Maury E; Blanchard HS; Chauvin P; Guglielminotti J; Alzieu M; Guidet B; Offenstadt G
    J Crit Care; 2003 Jun; 18(2):115-20. PubMed ID: 12800122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting endotoxin in the treatment of sepsis.
    Rachoin JS; Schorr CA; Dellinger RP
    Subcell Biochem; 2010; 53():323-38. PubMed ID: 20593274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
    Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
    Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current prospects for the treatment of clinical sepsis.
    Suffredini AF
    Crit Care Med; 1994 Jul; 22(7):S12-8. PubMed ID: 8026188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional and high potency probiotic preparations for oral bacteriotherapy.
    Famularo G; De Simone C; Matteuzzi D; Pirovano F
    BioDrugs; 1999 Dec; 12(6):455-70. PubMed ID: 18031194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endotoxin as a therapeutic target in septic shock.
    Corriveau CC; Danner RL
    Infect Agents Dis; 1993 Feb; 2(1):35-43. PubMed ID: 8162352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiendotoxin strategies.
    Hellman J; Warren HS
    Infect Dis Clin North Am; 1999 Jun; 13(2):371-86, ix. PubMed ID: 10340172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
    Opal SM
    Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.
    Giacometti A; Cirioni O; Ghiselli R; Mocchegiani F; Orlando F; Silvestri C; Bozzi A; Di Giulio A; Luzi C; Mangoni ML; Barra D; Saba V; Scalise G; Rinaldi AC
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2478-86. PubMed ID: 16801429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.